Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats

European Journal of Pharmacology

Volumn 584, Issue 2-3, 2008, Pages 285-290

  Kitaichi, Yuji ^a   Inoue, Takeshi ^a   Izumi, Takeshi ^a   Nakagawa, Shin ^a   Tanaka, Teruaki ^a   Masui, Takuya ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cabergoline; Dopamine; In vivo microdialysis; Milnacipran; Noradrenaline; Serotonin

Indexed keywords

AMINE; CABERGOLINE; MILNACIPRAN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; IN VIVO STUDY; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CYCLOPROPANES; DOPAMINE; DOPAMINE AGONISTS; DRUG INTERACTIONS; ERGOLINES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 41249089363     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.019     Document Type: Article

References (31)

1. Aronson R., Offman H.J., Joffe R.T., and Naylor C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53 (1996) 842-848
2. Bauer M., and Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol. 19 (1999) 427-434
3. Bouras N., and Bridges P.K. Bromocriptine in depression. Curr. Med. Res. Opin. 8 (1982) 150-153
4. Carboni E., Tanda G.L., Frau R., and di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55 (1990) 1067-1070
5. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11 (2000) 58-65
6. Cummings J.L. Depression and Parkinson's disease: a review. Am. J. Psychiatry 149 (1992) 443-454
7. Devoto P., Flore G., Pani L., and Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol. Psychiatry 6 (2001) 657-664
8. Devoto P., Flore G., Longu G., Pira L., and Gessa G.L. Origin of extracellular dopamine from dopamine and noradrenaline neurons in the medial prefrontal and occipital cortex. Synapse 50 (2003) 200-205
9. Goldberg J.F., Burdick K.E., and Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 161 (2004) 564-566
10. Inoue T., Tsuchiya K., Miura J., Sakakibara S., Denda K., Kasahara T., and Koyama T. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol. Psychiatry 40 (1996) 151-153
11. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., and Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. Affective Disord. 61 (2000) 127-132
12. Janicak P.G., Davis J.M., Preskorn S.H., and Ayd Jr. F.J. Principles and Practice of Psychopharmacotherapy. Third ed. (2001), Lippincott Williams & Wilkins, Philadelphia, USA
13. Kapur S., and Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry 32 (1992) 1-17
14. Kitaichi Y., Inoue T., Nakagawa S., Izumi T., and Koyama T. Effect of co-administration of lithium and reboxetine on extracellular monoamine concentrations in rats. Eur. J. Pharmacol. 489 (2004) 187-191
15. Koch S., Perry K.W., and Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacolgy 46 (2004) 232-242
16. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., Gemignani A., Battistini G., Bassi A., Abelli M., and Cassano G.B. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 4 (2002) 307-314
17. Lemke M.R., Fuchs G., Gemende I., Herting B., Oehlwein C., Reichmann H., Rieke J., and Volkmann J. Depression and Parkinson's disease. J. Neurol. 251 Suppl 6 (2004) 24-27
18. Mantegani S., Brambilla E., and Varasi M. Ergoline derivatives: receptor affinity and selectivity. Farmaco 54 (1999) 288-296
19. Mattes J.A. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann. Clin. Psychiatry 9 (1997) 87-88
20. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin A.J., and Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303 (2002) 791-804
21. 2 agonist, on reserpine-treated rodents. Biol. Pharm. Bull. 19 (1996) 1499-1502
22. 2-adrenoceptor. J. Pharmacol. Exp. Ther. 303 (2002) 805-814
23. Pan W.H., Yang S.Y., and Lin S.K. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Synapse 53 (2004) 44-52
24. Quintin P., and Thomas P. Efficacy of atypical antipsychotics in depressive syndromes. Encephale. 30 (2004) 583-589
25. Spencer C.M., and Wilde M.I. Milnacipran. A review of its use in depression. Drugs 56 (1998) 405-427
26. Takahashi H., Yoshida K., Higuchi H., Shimizu T., Inoue T., and Koyama T. Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenaline reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports. Clin. Neuropharmacol. 26 (2003) 230-232
27. Thase M.E., Corya S.A., Osuntokun O., Case M., Henley D.B., Sanger T.M., Watson S.B., and Dube S. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 68 (2007) 224-236
28. Theohar C., Fischer-Cornelssen K., Brosch H., Fischer E.K., and Petrovic D. A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneimittelforschung 32 (1982) 783-787
29. Waehrens J., and Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J. Affect. Disord. 3 (1981) 193-202
30. Waldmeier P.C., and Stocklin K. The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur. J. Pharm. 169 2-3 (1989) 197-204
31. 2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J. Psychopharmacol. 18 (2004) 395-403